GlassScriptPhysician profile
Ashish C Shah
NPI 1730287020
$4,842.78
in general payments reported to CMS, 2019-2025
53 companies · $1,031 in 2025
The $1,031 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,373 · 2020: $1,087 · 2021: $162 · 2022: $31.33 · 2023: $318 · 2024: $841 · 2025: $1,031.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,170 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,170.39 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,029.06 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $381.42 | 2019-2024 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $370.89 | 2019-2025 | Trelegy Ellipta |
| Lilly USA, LLC | $359.36 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $229.72 | 2019-2025 | Ubrelvy, Qulipta |
| Amgen INC. | $167.13 | 2019-2024 | Repatha, Otezla |
| Pfizer INC. | $161.90 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.77 | 2020-2025 | Jardiance, Synjardy |
| Astellas Pharma US INC | $141.72 | 2019-2025 | Veozah |
| Sanofi-Aventis U.S. LLC | $140.30 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $132.37 | 2019-2024 | |
| Abbott Laboratories | $129.45 | 2023-2024 | Mitraclip, Eterna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $126.45 | 2019-2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $86.85 | 2023-2025 | Rexulti, Nuedexta |
| Allergan, INC. | $86.84 | 2019-2020 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashish Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.